{"organizations": [], "uuid": "22bd7d6cc4f565928b2dc41e8c673dff5d14bd05", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "", "site_section": "http://www.reuters.com/finance/personal-finance", "section_title": "Wealth, Personal Finance &amp; Money | Reuters.com", "url": "http://www.reuters.com/article/2015/10/19/valeant-results-ceo-idUSL1N12J0PP20151019", "country": "US", "title": "Valeant CEO sees new drug pricing environment ahead", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "Valeant CEO sees new drug pricing environment ahead | Reuters", "spam_score": 0.0, "site_type": "news", "published": "2015-10-19T16:50:00.000+03:00", "replies_count": 0, "uuid": "22bd7d6cc4f565928b2dc41e8c673dff5d14bd05"}, "author": "Reuters", "url": "http://www.reuters.com/article/2015/10/19/valeant-results-ceo-idUSL1N12J0PP20151019", "ord_in_thread": 0, "title": "Valeant CEO sees new drug pricing environment ahead", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "NEW YORK Oct 19 Valeant Pharmaceuticals International Inc CEO J. Michael Pearson said on Monday that outside pressures are creating a new pricing environment for all pharmaceutical companies and that Valeant expects to keep increases to 10 percent or less next year.\nDuring a conference call with investors in which he defended the company's drug pricing strategy, Pearson said that Valeant has begun during the past two years to increase sales volumes as a percentage of growth compared with price increases.\n(Reporting by Caroline Humer )", "external_links": [], "published": "2015-10-19T16:50:00.000+03:00", "crawled": "2015-10-19T15:59:25.173+03:00", "highlightTitle": ""}